News

Important information

BIOJAMP : A Range of Biosimilars for a Seamless Approach

November 14, 2023
Alvotech and JAMP Pharma announce receipt of marketing authorization for PrJamtekiTM (AVT04), the first biosimilar of Stelara® (ustekinumab)
May 15, 2023
JAMP Pharma Group receives Health Canada approval for Pr JAMP Dapagliflozin, a new generic alternative for the treatment of type 2 diabetes
May 31, 2022
JAMP Pharma covers many therapeutic areas with medicines to treat a large number of diverse indications with close to 300 Rx and OTC molecules.
May 19, 2022
JAMP Pharma Group Launches PrJAMP Teriflunomide, a New Generic for the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis
October 15, 2021
New at Wampole : Ultra-C
April 10, 2021
New at Laboratoire Suisse: Anti-nausea liquid ginger
February 15, 2021
New at Laboratoire Suisse: Melatonin Gummies